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Abstract The guanylyl cyclases, GC-A and GC-B, are selec-
tive receptors for atrial and C-type natriuretic peptides (ANP
and CNP, respectively). In the anterior pituitary, CNP and GC-
B are major regulators of cGMP production in gonadotropes
and yet mouse models of disrupted CNP and GC-B indicate a
potential role in growth hormone secretion. In the current
study, we investigate the molecular and pharmacological prop-
erties of the CNP/GC-B system in somatotrope lineage cells.
Primary rat pituitary and GH3 somatolactotropes expressed
functional GC-A and GC-B receptors that had similar EC50
properties in terms of cGMP production. Interestingly, GC-B
signaling underwent rapid homologous desensitization in a
protein phosphatase 2A (PP2A)-dependent manner. Chronic
exposure to either CNP or ANP caused a significant down-
regulation of both GC-A- and GC-B-dependent cGMP
accumulation in a ligand-specific manner. However, this
down-regulation was not accompanied by alterations in the
sub-cellular localization of these receptors. Heterologous de-
sensitization of GC-B signaling occurred in GH3 cells follow-
ing exposure to either sphingosine-1-phosphate or
thyrotrophin-releasing hormone (TRH). This heterologous de-
sensitization was protein kinase C (PKC)-dependent, as pre-
treatment with GF109203X prevented the effect of TRH on
CNP/GC-B signaling. Collectively, these data indicate com-
mon and distinct properties of particulate guanylyl cyclase
receptors in somatotropes and reveal that independent mecha-
nisms of homologous and heterologous desensitization occur
involving either PP2A or PKC. Guanylyl cyclase receptors thus
represent potential novel therapeutic targets for treating growth-
hormone-associated disorders.
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Introduction
C-type natriuretic peptide (CNP) is the third member of the
natriuretic peptide family and is highly conserved between
species as diverse as elasmobranchs and humans (Fowkes and
McArdle 2000). The vast majority of CNP effects are medi-
ated via the specific guanylyl cyclase-B (GC-B) receptor,
encoded by the Npr2 gene and lead to a localized increase
in cyclic guanosine 3’,5’ monophosphate (cGMP) signaling
(Potter et al. 2006). CNP and GC-B are expressed in numer-
ous tissues, including the major endocrine glands and
throughout the central nervous system (Fowkes and
McArdle 2000; Potter et al. 2006). The anterior pituitary is a
major site of CNP expression, where it is predominantly
localized in gonadotropes (McArdle et al. 1993) and acts as
a local mediator of gonadotrope function (McArdle et al.
1994; Thompson et al. 2009). Mouse models of disrupted
CNP or GC-B (Nppc−/− and Npr2−/−, respectively) essential-
ly phenocopy one another, in that these animals suffer from
severe achrondroplasia and dwarfism, female infertility and
early death (Chusho et al. 2001; Tamura et al. 2004). In
addition, global Npr2−/− knock-out mice are also growth-
hormone-deficient, suggesting a pituitary phenotype
(Tamura et al. 2004). We have recently described the presence
of both NPPC and NPR2 transcripts in normal human pitui-
tary tissue of fetal and adult origin and in a range of pituitary
adenomas including those from acromegalic patients
(Thompson et al. 2012). Despite this, the major role for CNP
in pituitary function remains unclear.
Early studies indicate that atrial natriuretic peptide (ANP;
Inagaki et al. 1986) is expressed in the anterior pituitary and it
has been reported to act as a gonadotropin secretagog
(Horvath et al. 1986). However, specific preparations of
ANP were subsequently revealed to have been contaminated
with gonadotrophin-releasing hormone, which accounted for
the apparent effects of ANP on the secretion of luteinizing
hormone (Abou-Samra et al. 1987). Nevertheless, several
pharmacological studies support a functional role of ANP,
acting via GC-A receptors, in the anterior pituitary (McArdle
et al. 1993; Thompson et al. 2009; Gilkes et al. 1992; Fowkes
et al. 2000) but, in keeping with the current understanding of
the pituitary CNP system, the biological consequence of ANP
signaling in the pituitary is unclear. ANP probably performs
an alternative role to CNP, as genetic disruption to eitherNppa
(encoding ANP) or Npr1 (encoding the GC-A receptor) fails
to recapitulate the apparent growth hormone deficiency or
female infertility and early death (John et al. 1995; Lopez
et al. 1995).
Pharmacological regulation of the GC-B receptor has been
elegantly described through many studies by Potter and
Hunter (1998a, 1999) who have shown that dephosphoryla-
tion of specific serine and threonine residues of the GC-B
receptor leads to rapid homologous desensitization. In keep-
ing with the extensive literature describing the regulation of
GC-A receptors (Potter et al. 2006), enhancement of protein
kinase C (PKC) activity leads to heterologous desensitization
(Potter and Hunter 2000). Prolonged exposure to ANP or CNP
does not appear to cause agonist-induced internalization (Fan
et al. 2005; Dickey et al. 2011), although this remains a
controversial issue (Pandey 2005).Whereas these comprehen-
sive studies have elucidated mechanisms of GC-B desensiti-
zation, the vast majority of them characterize the function of
exogenously expressed receptors (Potter et al. 2006). In con-
trast, we have previously shown that endogenous GC-B re-
ceptors undergo both homologous and heterologous desensi-
tization in gonadotrope-derived αT3-1 cells (Fowkes et al.
2000) and have characterized an intact CNP/GC-B system
within gonadotropes and human pituitary tissue (Thompson
et al. 2009, 2012).
Despite studies suggesting an effect of CNP and GC-B
signaling in pituitary somatotropes (Hartt et al. 1995;
Shimekake et al. 1994), little is currently understood about the
natriuretic peptide system in these cells. In our current study, we
examine the molecular and functional characteristics of the
natriuretic peptide system in GH3 somatolactotropes and pri-
mary rat pituitaries. We describe an intact CNP/GC-B sys-
tem in both GH3 cells and rat pituitary tissue and provide
evidence for the regulation of GC-B signaling that in-
volves both homologous and heterologous desensitization
of cGMP signaling, potentially via a PKC-dependent




Materials and pharmacologic inhibitors were purchased either
from Calbiochem (MerckMillipore UK, Feltham, UK) or
Sigma (Sigma-Aldrich, Dorset, UK). GC-A (PGCA-101AP),
GC-B (PGCB-101AP) and β-actin (ab8226) primary anti-
bodies were purchased from Fabgennix (Frisco, Tex., USA)
or AbCam (Cambridge, UK). All secondary antibodies were
from DAKO (Cambridge, UK).
Cell culture
GH3 cells were maintained in high-glucose DMEM (Sigma),
supplemented with 10 % (v/v) fetal calf serum (FCS; Sigma),
100 U penicillin/ml and 100 μg streptomycin sulfate/ml
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(Sigma) in 5 % CO2 humidified air at 37 °C, as described
previously (Fowkes and Burrin 2003). These growth hormone
and prolactin-secreting cells were originally derived from
Wistar-Furth rats with pituitary tumors (Tashjian et al. 1968;
Faivre-Bauman et al. 1975) and express functional
thyrotrophin-releasing hormone (TRH) receptors (Hinkle
and Tashjian 1973) but not growth-hormone-releasing hor-
mone receptors (Zeytin et al. 1984). Consequently, they are
considered a hybrid somatolactotrope-derived cell line.
RNA extraction and polymerase chain reaction
Total RNAwas extracted from 1×106 GH3 cells or frommale
Sprague Dawley rat pituitaries by using Tri-reagent (Sigma-
Aldrich, Poole, UK) and subjected to DNase treatment
(Qiagen, Manchester, UK) before generation of first-strand
cDNA (Applied Biosystems, Warrington, UK). Polymerase
chain reaction (PCR) was performed for a range of targets for
30 cycles by using the primers and conditions published
previously (Thompson et al. 2009). In some instances, GH3
cells were treated with 0 or 100 nM CNP for 24 h prior to
RNA extraction. These samples were processed for qualitative
PCR (qPCR) analyses with commercially available rat Npr2
and 18S primer sets (Qiagen,Manchester, UK) under standard
SYBR conditions as described previously (Bayol et al. 2010).
Immunoblotting
GH3 cell lysates (from 1×106 cells) were prepared in lysis
buffer (0.5 M TRIS pH 6.8, 10 % [v/v] glycerol, 1 % [w/v]
SDS). Protein lysates were sonicated, boiled at 95 °C for
5 min, resolved by 10 % SDS-polyacrylamide gel electropho-
resis, transferred to polyvivylidene difluoride membrane and
probed for GC-B (1:2000 dilution) or β-actin (1:5000 dilu-
tion) expression. Appropriate horseradish-peroxidase-
conjugated secondary antibodies were purchased from
DAKO.
cGMP enzyme-immunoassay to measure total cGMP
accumulation
GH3 cells were plated and underwent the respective treat-
ments in physiological saline solution (PSS; 127 mM NaCl,
1.8 mM CaCl2, 5 mM KCl, 2 mMMgCl2, 0.5 nM NaH2PO4,
5 mM NaHCO3, 10 mM glucose, 0.1 % BSA, 10 mM
HEPES, adjusted to pH 7.4). All pre-treatments were per-
formed in the absence of 3-isobutyl-1-methylxanthine
(IBMX), whereas all stimulations were performed in the pres-
ence of 1 mM IBMX. Each reaction was terminated with the
addition of ice-cold 100 % (v/v) ethanol and the samples were
dried down under vacuum as described previously
(Thompson et al. 2009). Reagents and standards were pre-
pared by using the instructions supplied with the cGMP
enzyme-immunoassay kit (R&D Systems, Abingdon, UK).
The optical density of each sample at 450 nm was determined
by means of an Berthold Technologies Mithras LB940 plate
reader with MicroWin 4.40 associated software (Berthold
Technologies, Harpenden, UK).
Immunofluorescence cytochemistry
GH3 cells were mounted on poly-L-lysine-coated coverslips
and treated with either 0 or 100nM ANP or CNP in PSS
during the indicated time points. Following treatment, cells
were fixed with 4 % (w/v) formaldehyde for 10 min at room
temperature and permeabilized with buffer (1 % [v/v] Tween-
20 in 50 ml phosphate-buffered saline [PBS]) before incuba-
tion for 10 min at room temperature. Cells were then blocked
with 3 M sodium azide dissolved in 92 % PBS, 3 % FCS and
5 % Tween-20 (v/v) for 20 min at room temperature, washed,
then exposed to 1:200 diluted primary antibody solution (GC-
A or GC-B, plus 0.1 % FCS and 0.1 % Tween-20) for 16 h at
4 °C. After further washes and a 5-min PBS immersion at
room temperature, secondary antibody was added plus
phalloidin-rhodamine β-actin (Invitrogen, Paisley, UK) and
4,6-diamidino-2-phenylindole (DAPI) nuclear counterstains
(Vector Laboratories, Peterborough, UK) and incubated for
45 min at room temperature. Following three PBS washes and
a final 5-min PBS immersion at room temperature, the slides
were mounted in Vectorshield (Vector Laboratories,
Peterborough, UK) on standard VWR (VWR International,
Leicestershire, UK) slides ready for analysis. A Leica SPS
confocal scanning laser microscope was used to capture the
staining, which was analyzed with Leica SPS software (Leica
Microsystems, Milton Keynes, UK).
Statistical analyses
All graphs were generated and statistical analyses were per-
formed by using Prism software (Prism 5.0 for Mac OS X,
Graphpad Software, Calif., USA). Unless otherwise stated,
one-way analysis of variance followed by post-hoc Bonferroni
Multiple Comparison Tests were carried out to determine statis-
tical significance (at P <0.05). Numerical data presented in this
manuscript represent the means±SEM from at least three inde-
pendent experiments, each performed in triplicate.
Results
Molecular and pharmacological characterization of natriuretic
peptide receptors in GH3 somatolactotropes and primary rat
pituitary tissue
Our previous studies have revealed that Npr1 , Npr2 , Npr3
and Nppc are all expressed in mouse pituitaries and/or in
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gonadotropes, suggesting a local role in the regulation of
reproduction (Thompson et al. 2009). However, Npr2−/− not
only are infertile but also have dwarfism and growth hormone
deficiencies, suggesting that natriuretic peptides and their
receptors also control somatotropes. To establish which
guanylyl cyclases the GH3 somatolactotropes express, total
RNA was extracted from GH3 cells and normal rat pituitary
tissue, before qualitative reverse transcription (RT)-PCR. As
shown (Fig. 1a), in GH3 cells, specific transcripts were de-
tected for Npr1 (GC-A), Npr2 (GC-B1, GC-B2) and the
somatotrope transcription factor, Pou1f1 (Pit1). Interestingly,
no expression of Npr3 (clearance receptor) was detectable. In
contrast, specific transcripts were detected for all these genes
in primary rat pituitary tissue.
To establish whether functional GC-A and GC-B receptors
were expressed in GH3 cells, we determined the effects of ANP
and CNP on cGMP accumulation. GH3 cells were treated for
15 min with the indicated concentrations of natriuretic peptide,
in the presence of 1 mM IBMX to inhibit phosphodiesterase
activity. As shown (Fig. 1b, c), both ANP and CNP caused
concentration-dependent increases in cGMP accumulation in
GH3 cells (ANP EC50~45.7 nM, CNP EC50~53.7 nM).
Evidence of homologous desensitization of endogenous
GC-A- and GC-B-mediated signaling in GH3 cells
To characterize the activity of these receptors further , a series
of experiments was performed to examine mechanisms of
receptor desensitization. Total cGMP accumulation was mea-
sured to determine the changes in activity of the GC-A andGC-
B receptors when treated over a short time-course with their
native ligands, namely ANP and CNP, respectively. GH3 cells
were plated at 3 × 105 cells/well in a 24-well plate, treated with
100 nM of either ANP or CNP in the presence of the phospho-
diesterase inhibitor IBMX (1 mM) for 0 to 15 min and assayed
for total cGMP concentration (Fig. 2a, b). From 0–5 min of
treatment with 100 nM CNP, a rapid increase in cGMP accu-
mulation was seen from 6.4±0.7 to 82.7±15.5 pmol/ml per
milligram protein. In contrast, cGMP accumulation between 5
to 15 min of treatment with 100 nM CNP (82.7±15.5 to
117.4±17.6pmol/ml per milligram protein) was significantly
attenuated compared with that seen over the first 5 min (re-
duced to 22.2±3.9% of the initial rate of accumulation between
0 to 5 min; ***P <0.001). This failure to maintain the initial
rate of cGMP accumulation suggested that rapid homologous
desensitization of GC-B-mediated cGMP signaling had oc-
curred. In another experiment performed with 100 nM ANP
instead of CNP, a rapid increase in cGMP accumulation
(7.91±0.9 to 164.31±9.1pmol/ml per milligram protein)
occurred between 0 and 5 min. In contrast to GC-B, this initial
rate of cGMP accumulation was maintained for at least
15 min, suggesting that rapid homologous desensitization of
GC-A-mediated cGMP signaling did not occur (Fig. 2b).
As previous studies have suggested that receptor dephos-
phorylation mediates desensitization of GC-B receptors
(Potter 1998), the effect of inhibiting protein phosphatases
was examined. As ANP failed to desensitize the GC-A recep-
tor in these studies within 15 min, the effects of protein
phosphatase (PP) inhibitors on GC-B were examined instead.
Similar short time-courses were performed, except that some
cells were pre-treated with 100 nM okadaic acid (OA, a PP2A
inhibitor), 1 nM cypermethrin (a PP2B inhibitor), or 1 mM
sodium orthovanadate (Na3VO4, a protein tyrosine phospha-
tase inhibitor) for 30 min prior to CNP treatment (Fig. 2c). As
expected, control cell response to CNP underwent desensiti-
zation as shown by the failure to maintain the initial rate of
cGMP accumulation. The initial rate of cGMP accumulation
between 0 and 5min was not significantly affected by any pre-
treatments. Interestingly, cells pre-treated with OA main-
tained a significant rate of cGMP accumulation from 5 to
Fig. 1 Molecular and pharmacological characterization of natriuretic
peptide receptors in GH3 somatolactotropes and primary rat pituitary
tissue. a Total RNAwas extracted from either GH3 cells or primary rat
pituitaries, prior to cDNA synthesis and reverse transcription plus the
polymerase chain reaction for the indicated gene targets. Data shown are
representative of at least three independent experiments. b , c GH3 cells
were stimulated with the indicated concentrations of (b) atrial natriuretic
peptide (ANP) or (c) C-type natriuretic peptide (CNP) in physiological
saline solution (PSS) containing 1 mM 3-isobutyl-1-methylxanthine
(IBMX) for 15 min, before termination with 100 %(v/v) ice-cold ethanol.
Following extraction under vacuum, total cGMP accumulation was mea-
sured by enzyme-immunoassay and concentration-response curves were
constructed by using pre-existing equations in GraphPad Prism 5.0. The
data shown are means ± SEM of three independent experiments, each
performed in triplicate and are expressed as pmol/mg protein (n=3)
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15 min (r2=0.69, **P <0.01), whereas cypermethrin- and
Na3VO4-treated cells failed to maintain a significant rate of
cGMP accumulation, indicating a potential role for PP2A but
not PP2B or tyrosine phosphatases, in mediating homologous
desensitization of GC-B signaling in GH3 cells.
Effect of pre-treatment on GC-A and GC-B receptor signaling
in GH3 cells
Having established that GC-B signaling but not that of GC-A
receptors, underwent rapid homologous desensitization, we next
examined the effect of prolonged exposure of each receptor to
its specific ligand. GH3 cells pre-treated with either ANP or
CNP for 0 (control) to 6 h reduced the response to a subsequent
15-min treatment of ANP or CNP (with IBMX). GH3 cells pre-
treated with 100 nM CNP demonstrated a significant reduction
in cGMP produced compared with the control response to CNP
(no CNP pre-treatment). The amount of cGMP measured from
the 15-min pre-treatment sample was reduced by 39.6±0.002%
(***P <0.001). This effect was maintained up to the 6-h pre-
treatment with CNP, which was reduced by 37.9±7.1 % com-
pared with the control (***P <0.001). The reduction in cGMP
Fig. 2 Rapid homologous
desensitization of CNP-
dependent but not ANP-
dependent cGMP accumulation in
GH3 cells. Cells were treated with
PSS containing either (a) 100 nM
CNP or (b) 100 nM ANP for
0–15min in the presence of 1 mM
IBMX. The data shown are
means ± SEM of three
independent experiments, each
performed in triplicate and are
expressed as pmol/ml per
milligram protein
(n =3). The bar charts (right)
indicate a comparison of the rate
of cGMP accumulation between
0 and 5 min and between 5 and
15 min of stimulation
(***P <0.001, significantly
different from the rate of cGMP
accumulation between 0 and
5 min). c GH3 cells were treated
as before with 100 nM CNP from
0 to 15 m in the presence or
absence of either the protein
phosphatase 2A (PP2A) inhibitor,
okadaic acid (OA , 100 nM), the
PP2B inhibitor, cypermethrin
(1 nM), or the protein tyrosine
phosphatase inhibitor, sodium
orthovanadate (Na3VO4, 1 mM)
and assayed for total cGMP
concentration. The data are means
± SEM of three independent
experiments, each performed in
triplicate and are expressed as the
fold change in the rate of cGMP
accumulation between 5 and
15 min (n =3; **P <0.01, cGMP
accumulation maintained at a
significant rate)
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accumulation compared with the control did not significantly
differ between the 15-min to 6-h pre-treatments (not significant
[ns], P >0.05; Fig. 3a), suggesting that maximal desensitization
of GC-B signaling occurred within 15 min of pre-treatment.
In similar experiments designed to examine the effect of
ANP pre-exposure to GC-A activity, a significant reduction in
cGMP accumulation was observed within 30min of ANP pre-
treatment (by 28.9±3.1 % compared with the control,
*P <0.05). This inhibitory effect was maintained throughout
the 6-h pre-treatment (*P <0.05). Interestingly, GH3 cells pre-
treated with ANP for 15 min did not show a significant
reduction in cGMP accumulation compared with the control
(ns, P >0.05; Fig. 3b). In order to test the receptor specificity
of the observed down-regulation of GC-B upon pre-treatment
with CNP and of GC-A upon pre-treatment with ANP, the
effects of ANP on GC-B and CNP on GC-A desensitization
were determined. GH3 cells pre-treated with 100 nMCNP for
6 h caused a significant 37.9±7.1 % (*P <0.05) reduction in
cGMP when subsequently treated with 100 nM CNP plus
IBMX for 15 min, compared with the control. The amount
of cGMP measured from the ANP pre-treated cells was not
significantly different from the control samples (ns, P >0.05;
Fig. 3c). Pre-treating GH3 cells with 100 nM ANP for 6 h
resulted in a significant 50.0±7.7 % (*P <0.05) reduction in
cGMP produced when cells were then treated with 100 nM
ANP plus IBMX for 15 min, compared with the control. The
amount of cGMP measured from the CNP pre-treated cells
was not significantly different from the control samples (ns,
P >0.05; Fig. 3d). Collectively, these data suggest that ho-
mologous desensitization occurs for both ANP- and CNP-
dependent signaling, whereas cross-desensitization of GC-A
and GC-B signaling does not. This further suggests that these
ligands are exerting their effects via their specific cognate
receptors in GH3 cells.
CNP-induced down-regulation of Npr2 mRNA or GC-B
protein does not occur in GH3 cells
We next examined whether Npr2 or GC-B down-regulation
(as determined by a reduction in Npr2 mRNA expression and
or GC-B protein expression) mediated the inhibitory effects of
sustained CNP exposure. The effect of CNP exposure on the
Fig. 3 Effect of chronic exposure
to CNP and ANP on GC-B- and
GC-A-dependent cGMP
accumulation in GH3 cells. Cells
were initially treated with (a)
100 nMCNP or (b) 100 nMANP
in PSS without IBMX for 0 to 6 h.
The medium was removed and
replaced with 100 nMCNP (a) or
100 nM ANP (b) for 15 min in
the presence of 1 mM IBMX. The
data shown are means ± SEM of
three independent experiments,
each performed in triplicate and
are expressed as the percentage of
the control (n=3). ***P <0.001,
*P<0.05, significantly different
from the control. c , d Cells were
initially treated with 0, 100 nM
CNP, or 100 nM ANP for 6 h as
before. All pre-treatments were
removed and replaced either with
(c) 0 or 100 nM CNP or with (d)
0 or 100 nM ANP, for 15 min in
the presence of 1 mM IBMX. The
data shown are means ± SEM of
three independent experiments,
each performed in triplicate and
are expressed as the percentage of
the control (n=3). *P<0.05,
significantly different from the
control
430 Cell Tissue Res (2014) 355:425–436
expression of the endogenous Npr2 gene was examined by
using qPCR. A 24-h treatment with 100 nM CNP failed to
alter Npr2 expression in GH3 cells (Fig. 4a). To establish
whether down-regulation occurred at the protein level, total
proteins were extracted from GH3 cells incubated for up to
24 h with 100 nM CNP. Western blotting for GC-B protein
revealed that CNP failed to alter expression levels (Fig. 4b).
Collectively, these data suggest that a loss of Npr2 mRNA or
GC-B protein is not responsible for the reduced cGMP accu-
mulation seen in pre-treated GH3 cells.
Agonist-induced internalization does not accompany GC-A
or GC-B desensitization
To determine whether the GC-A or GC-B receptors undergo
internalization upon stimulation with their respective ligands,
confocal microscopy for GC-A and GC-B was used to visu-
alize this process directly. Representative immunofluores-
cence for GC-A- and GC-B-labeled GH3 cells are shown
(Fig. 5a–f). GH3 cells treated with 100 nM CNP or 100 nM
ANP for 0–4 h did not demonstrate any observable GC-B or
GC-A internalization, as observed by the overlay of the stain-
ing for actin filaments with that for GC-B and GC-A.
Heterologous desensitization of GC-B signaling involves
sphingolipid and calcium signaling in GH3 cells
Sphingolipids and calcium have been implicated in regulating
natriuretic peptide signaling (Abbey-Hosch et al. 2004; Abbey
and Potter 2002). Therefore, we examined the role of
sphingosine-1-phosphate (S1P) on CNP-stimulated cGMP
accumulation. Pre-treating GH3 cells with 10 μM S1P for
30 min failed to significantly alter basal cGMP accumulation
(Fig. 6a). However, S1P pre-treatment did cause desensitiza-
tion of CNP-stimulated cGMP accumulation (by 30±2.7 %
compared with control, **P <0.01). Interestingly, pre-treating
GH3 cells with 10 μM S1P did not result in desensitization of
ANP-stimulated cGMP accumulation, compared with the
ANP control samples (Fig. 6b; ns, P >0.05), suggesting that
GC-B and GC-A receptors are differentially regulated in GH3
cells. In similar experiments, cells were pre-treated with either
0 or 10 μMA23187 for 30 min prior to stimulation with either
0, 100 nM CNP, or 100 nM ANP for 15 min; however, pre-
treatment with this calcium ionophore failed to alter either
CNP- or ANP-stimulated cGMP accumulation (Fig. 6c, d).
Heterologous desensitization of GC-B signaling involves
PKC but not cAMP signaling in GH3 cells
Subsequent experiments examined the potential regulation of
GC-B signaling by other peptide hormones. To determine
whether the GC-B receptor underwent heterologous desensi-
tization in GH3 cells, the effect of three known activators of
PKC on CNP-stimulated cGMP accumulation was analyzed.
Pre-treatment with TRH, with the phorbol ester, phorbol-12-
myristate-13-acetate (PMA), or with pituitary adenylate
cyclase-activating polypeptide (PACAP) failed to alter
basal cGMP accumulation (ns, P >0.05). However, cells
pre-treated with 100 nM TRH or PMA showed a sig-
nificant reduction in CNP-stimulated cGMP accumulation
compared with the control (44.6±2.5 % and 51.9±2.8 %,
respectively, ***P <0.001). Pre-treating the GH3 cells with
100 nM PACAP failed to alter CNP-stimulated cGMP accu-
mulation (ns, P >0.05; Fig. 7a). To establish whether the
TRH-induced heterologous desensitization of GC-B signaling
was PKC-dependent, GH3 cells were pre-treated with either 0
or 1 μMGF109203X for 30 min to inhibit PKC activity. After
this, cells were further pre-treated in the absence or presence
of GF109203X and 0 or 100 nM TRH for a further 30 min,
prior to stimulation with 0 or 100 nM CNP for a final 15-min
Fig. 4 CNP fails to alter expression of Npr2 mRNA or GC-B protein in
GH3 somatolactotrope cells. a GH3 cells were stimulated with 0 or
100 nM CNP for 24 h prior to extraction of total RNA, cDNA synthesis,
and quantitative PCR for endogenous Npr2 expression. The data shown
are means ± SEM of three independent experiments (n=3). b GH3 cells
were stimulated with 100 nM CNP for the indicated time, prior to
extraction of total protein andWestern blot analysis for GC-B expression.
Blots were stripped and re-probed forβ-actin. Panels are representative of
three independent experiments (n =3)
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stimulation in the presence of 1 mM IBMX. As shown
(Fig. 7b), TRH pre-treatment caused the expected heterologous
desensitization in GC-B signaling (to 20.1±5.4 %, P <0.001
compared with control) but this desensitization was pre-
dominantly reversed in the presence of GF109203X (to
76.4±17.2 %, ns compared with control). Collectively, these
data suggest that TRH, via the activation of PKC, causes
heterologous desensitization of GC-B in GH3 cells.
Discussion
Early expression profiling of CNP established the anterior
pituitary as being a major site of expression and action
(McArdle et al. 1993; Thompson et al. 2009; Fowkes et al.
2000; Sudoh et al. 1990; Komatsu et al. 1991). Whereas our
previous studies have focused on the natriuretic peptide sys-
tem of gonadotrope-lineage cells (McArdle et al. 1993;
Thompson et al. 2009; Fowkes et al. 1999, 2000), data from
mouse models of disrupted CNP or GC-B have indicated a
potential deficiency in growth hormone secretion (Chusho
et al. 2001; Tamura et al. 2004), raising the intriguing possi-
bility that CNP/GC-B are involved in regulating somatotrope
function. In the current study, expression profiling in
somatolactotrope-derived GH3 cells has indicated the pres-
ence of both GC-A and GC-B receptors, which exhibit potent
activation by either ANP or CNP in terms of cGMP accumu-
lation, with similar EC50 properties. Despite these similar
Fig. 5 Lack of ligand-dependent
internalization of GC-B or GC-A
in GH3 somatolactotrope cells.
GH3 cells were cultured on glass
coverslips for 24 h prior to being
treated with either 100 nM CNP
for 0 (a), 1 h (b), or 4 h (c), or
100 nMANP for 0 (d), 1 h (e), or





phalloidin was used to detect the
actin cytoskeleton (red). Nuclear
localization was detected by using
4,6-diamidino-2-phenylindole
(DAPI) stain for orientation
(blue). Panels are representative
of three independent experiments
(n =3). Magnification ×40
Fig. 6 Evidence of sphingosine-mediated but not calcium-mediated,
heterologous desensitization of GC-B signaling in GH3 somatolactotrope
cells. GH3 cells were pre-treated with PSS containing either (a , b) 10μM
sphingosine-1-phosphate (S1P) or (c , d) 1 μM A23187 (calcium iono-
phore) for 30 min in the absence of IBMX, before a 15-min stimulation
with either 100 nM CNP (a , c) or 100 nMANP (b , d) in the presence of
1 mM IBMX. The data are means ± SEM of three independent experi-
ments, each performed in triplicate and are expressed as pmol/mg protein
(n =3). **P <0.01, significantly different from control response to CNP
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pharmacological properties, GH3 cells probably express more
GC-A receptors, as the maximal response to ANP is almost
twice that of CNP. However, our previous studies of primary
cultures of rat pituitary cells indicated a more comparable
effect of these peptides on cGMP accumulation (Thompson
et al. 2009), potentially reflecting differences between primary
and immortalized cells but also the relative ratio of GC-A and
GC-B expression in the different cell types.
The desensitization of natriuretic peptide receptors has
been extensively studied in cell lines stably transfected with
GC-A or GC-B (Potter and Hunter 1998a, 1998b; Potter and
Garbers 1994) and typically involves the dephosphorylation
of key Ser and Thr residues (Potter 1998). However, studies
reporting the desensitization of endogenous GC-A and GC-B
are limited (Fowkes et al. 2000; Müller et al. 2006). Our
current data represent the first demonstration that the desensi-
tization of endogenous GC-A and GC-B signaling occurs in
GH3 somatotrope cells.
Experimental paradigms to investigate receptor desensiti-
zation are often performed in one of two ways: time-course
studies of a single continuous exposure to ligand or pre-
treatment and subsequent re-exposure to the same ligand.
Our current studies involved the use of both of these ap-
proaches to examine particulate guanylyl cyclase signaling
in GH3 cells, similar to previous studies investigating PACAP
signaling in gonadotropes (McArdle and Forrest-Owen 1997).
Time-course studies of CNP-stimulated cGMP accumulation in
GH3 cells have shown a rapid elevation of cGMP levels within
5 min of CNP treatment, reflecting the activation of GC-B
receptors. Importantly, the continued accumulation of cGMP
between 5 to 15 min of CNP treatment does not significantly
increase, suggesting that CNP-stimulated cGMP accumulation
in GH3 cells undergoes rapid homologous desensitization. This
is in agreement with the effects of CNP on GC-B signaling in
αT3-1 cells (Fowkes et al. 2000) and suggests that potential
autocrine or paracrine effects of CNP in both somatotrope/
lactotrope and gonadotrope lineage cells can be regulated by
homologous desensitization. Interestingly, the same rapid ho-
mologous desensitization is not observed in the presence of
ANP suggesting that the mechanisms of GC-A and GC-B
desensitization differ in GH3 cells. One potential explanation
for the lack of rapid homologous desensitization of ANP sig-
naling in GH3 cells might be the apparent abundance of GC-A
receptors compared with GC-B receptors. Certainly, the qRT-
PCR Npr1 expression data, coupled with the potent
concentration-response curve of ANP-stimulated cGMP accu-
mulation in GH3 cells, support this interpretation. As the recep-
tor number is known to influence receptor desensitization
(Rousseau et al. 1997), ANP-stimulated cGMP accumulation
might not result in rapid homologous desensitization of GC-A
receptors within the short 15-min time-course in the current
studies.
Dephosphorylation of exogenously expressed GC-A or
GC-B receptors has long been established as a major mecha-
nism by which natriuretic peptide signaling is regulated
(Potter et al. 2006; Potter and Garbers 1992, 1994; Yoder
Fig. 7 Protein kinase C (PKC)-dependent heterologous desensitization
mediates the effects of thyrotrophin-releasing hormone (TRH) on CNP-
stimulated GC-B signaling in GH3 somatolactotrope cells. a GH3 cells
were pre-treated with PSS containing either 0 or 100 nM TRH, phorbol-
12-myristate-13-acetate (PMA), or pituitary adenylate cyclase-activating
polypeptide (PACAP) for 30 min in the absence of IBMX, before a 15-
min stimulation with either 0 or 100 nM CNP in the presence of 1 mM
IBMX. The data are means ± SEM of three independent experiments,
each performed in triplicate and are expressed as % control reponse to
CNP (n =3). ***P <0.001, significantly different from control response
to CNP. b GH3 cells were pre-treated with PSS containing either 0 or
1 μM GF109203X for 30 min and a subsequent pre-treatment with 0 or
100 nM TRH in the continued absence or presence of GF109203X,
before a 15-min stimulation with either 0 or 100 nM CNP in the presence
of 1 mM IBMX. The data are means ± SEM of three independent
experiments, each performed in triplicate and are expressed as % control
reponse to CNP (n=3). ***P<0.001, significantly different from control
response to CNP
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et al. 2012). Therefore, in order to determine whether the rapid
homologous desensitization of endogenous GC-B receptors in
GH3 cells was also dependent upon dephosphorylation, we
examined the effect of inhibiting protein phosphatase activity.
The selective PP2A inhibitor, OA, partially reversed the fail-
ure to maintain the initial rate of cGMP accumulation.
However, inhibition of PP2B activity with cypermethrin or
protein tyrosine phosphatases with Na3VO4 failed to reverse
the apparent homologous desensitization, suggesting that
PP2A but not PP2B or protein tyrosine phosphatases, activity
was required for the regulation of GC-B signaling in GH3
cells. Our novel observations, namely that GC-B receptors are
potential targets of PP2A-mediated dephosphorylation, indi-
cate potential new targets for manipulating natriuretic peptide
signaling. Recent studies investigating endogenous GC-A
receptors inMA-10 Leydig cells have shown that homologous
desensitization of these receptors is partially mediated selec-
tively through calcineurin/PP3 (Henesy et al. 2012). Thus,
tissue-specific phosphatase-specific control of guanylyl cy-
clase desensitization probably represents an emerging layer
of complexity in the control of these receptors.
To extend our investigations of GC-A and GC-B signaling
in GH3 cells, we used an alternative treatment paradigm to
establish whether pre-exposure to ligand could cause desensi-
tization to subsequent stimulation with either ANP or CNP.
By using this approach, both GC-A and GC-B receptors
appeared to undergo homologous desensitization in GH3
cells. Therefore, in addition to undergoing rapid homologous
desensitization, the GC-B receptor in GH3 cells can be regu-
lated by CNP over a prolonged period of time. Although the
GC-A receptors appear to undergo homologous desensitiza-
tion following prolonged exposure to ANP, this effect is not
significant until at least 30 min of ANP pre-treatment. This
discrepancy between the rates of onset of desensitization
between GC-B and GC-A can be explained either by a distinct
mechanism of desensitization compared with GC-B receptors
or as being attributable to a difference in GC-A receptor
number, as mentioned previously. Rapid homologous desen-
sitization of endogenous GC-A receptors has been reported in
MA-10 Leydig cells (Müller et al. 2006) suggesting that GC-
A regulation may well be cell-type specific and thus warrants
further investigation to establish the mechanism(s) involved.
As activation of either GC-B or GC-A signaling leads to an
increase in cGMP concentrations, we examined whether stim-
ulation of each receptor would lead to the desensitization of
the other receptor. Both ANP and CNP can activate the
reciprocal receptor, albeit only at pharmacological concentra-
tions (Suga et al. 1992). Our demonstration of desensitization
of GC-B and GC-A receptors in GH3 cells might not be
entirely attributable to the consequence of elevated cGMP
signaling, since neither ANP or CNP pre-treatment cause
subsequent desensitization of their reciprocal receptors, al-
though this might reflect the importance of receptor-specific
sub-cellular compartmentalized cGMP production. These
findings are in agreement with those observed in αT3-1 cells
(Fowkes et al. 2000) in which ANP and CNP fail to desensi-
tize the other receptor.
Prolonged exposure of GC-B receptors to CNP in GH3
cells might result in receptor down-regulation and internaliza-
tion. In the current study, we failed to see any significant effect
of prolonged exposure to CNP on endogenous Npr2 mRNA
or protein levels. Furthermore, GC-B immunoreactivity in
GH3 cells co-localized with a marker of the cytoskeleton
and was unaltered following CNP treatment. These observa-
tions suggest that rapid alterations in either the expression or
localization of the GC-B receptor do not occur in GH3 cells.
This lack of ligand-induced receptor internalization is in
agreement with previous studies in 293 T cells (Fan et al.
2005). Internalization of GC-A and GC-B remains a contro-
versial issue, as a number of studies have shown GC-A
internalization in PC-12 cells and MA-10 cells (Rathinavelu
and Isom 1991; Pandey 1993). However, several other studies
have failed to demonstrate such internalization (Koh et al.
1992; Vieira et al. 2001) raising the possibility that the inter-
nalization of guanylyl cyclase receptors is a cell-type-specific
phenomenon.
Heterologous desensitization of the natriuretic peptide re-
ceptors has been widely reported. Sphinogosine signaling is
implicated in GC-B desensitization in NIH3T3 fibroblasts,
A10 vascular smooth muscle cells and 293 T cells (Abbey-
Hosch et al. 2004, 2005). These studies have revealed that the
mechanism responsible for the S1P desensitization does not
require PKC activation but is reliant on the elevation of
intracellular Ca2+ levels, with ionomycin having a similar
effect. In the current study, we observed a modest effect of
S1P pre-treatment of CNP-stimulated cGMP accumulation in
GH3 cells but ANP-stimulated cGMP accumulation is unaf-
fected. Furthermore, the calcium ionophore A23187 has no
effect on either GC-B or GC-A signaling, suggesting that
particulate guanylyl cyclase signaling in GH3 cells is less
sensitive to changes to intracellular calcium levels, as is the
situation in gonadotrope-derived αT3-1 cells (McArdle et al.
1993).
The other major mechanism mediating heterologous de-
sensitization of GC-A and GC-B signaling is the PKC path-
way (Potter et al. 2006). We examined the effects of pre-
treatment with TRH, PMA, or PACAP. Pre-treatment with
PACAP fails to alter GC-B activity suggesting that limited
activation of PKC occurs in response to PACAP in GH3 cells.
This is in agreement with the predominant expression of
vasoactive intestinal peptide activated receptor 2, which is
known preferentially to activate cAMP and PKA (Hao et al.
2006). In contrast, pre-treatments with two known activators
of PKC, TRH and PMA do cause a significant reduction in
GC-B activity. PMA has previously been shown to desensitize
GC-B activity in 293 T cells and αT3-1 cells (Fowkes et al.
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2000; Abbey-Hosch et al. 2005). The novel observation that
TRH can cause the heterologous desensitization of GC-B
signaling in GH3 cells is at least partially dependent upon
PKC activity, because GF109203X is capable of reversing the
effect, as has been described previously in human airway
smooth muscle cells (Hamad and Knox 1999). We have
previously shown that another known activator of PKC,
namely gonadotrophin-releasing hormone, can cause the het-
erologous desensitization of GC-B signaling in αT3-1 cells
(McArdle et al. 1994; Fowkes et al. 2000). PKC-dependent
heterologous desensitization of GC-B is thought to increase
the activity of a protein phosphatase that specifically dephos-
phorylates Ser523 (Potter and Hunter 2000). Establishing the
identity of this phosphatase will reveal a potential therapeutic
target by which to regulate guanylyl cyclase signaling.
Both humans and mice with mutations in the genes
encoding either CNP or its receptor, GC-B, suffer from severe
growth disorders (Chusho et al. 2001) and, in some cases,
growth hormone deficiency (Tamura et al. 2004). Despite
significant homology between the three natriuretic peptides
and between their receptors, mutations in the genes encoding
ANP, BNP, or GC-A fail to phenocopy CNP/GC-B-disrupted
mice (Kishimoto et al. 2011). Our recent observations of GC-
B expression in normal fetal pituitary tissue and in a range of
human pituitary adenomas (including those from acrome-
galics) strongly support a pituitary role for CNP and GC-B
signaling, particularly within somatotrope-lineage cells
(Thompson et al. 2012). Our current findings that endogenous
GC-B receptors in GH3 cells are sensitive to both homologous
and heterologous desensitization, without apparent down-
regulation or internalization, provide an opportunity to ma-
nipulate GC-B/cGMP signaling in somatotropes. Given that
both CNP and cGMP have previously been shown to act as
growth hormone secretogogs (Hartt et al. 1995; Shimekake
et al. 1994), we are tempted to speculate that such manipula-
tion of guanylyl cyclase signaling might offer potential ther-
apies for growth-related disorders.
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